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Summary
Background:  Blood  conservation  strategies  have  been  developed  to  diminish  blood  transfusion
requirements  in  patients  undergoing  hip  or  knee  replacement  surgery.  Tranexamic  acid  (TA)  is  an
inexpensive  antiﬁbrinolytic  agent  that  is  little  used  in  orthopaedic  surgery  due  to  the  absence
of standardised  optimal  administration  regimens.
Hypothesis:  Blood  transfusion  requirements  and  induced  costs  can  be  diminished  by  using  TA
according  to  a  standardised  administration  protocol  in  a  large  cohort  of  patients.
Materials  and  methods:  A  retrospective  study  in  patients  who  underwent  joint  replacement
surgery by  a  single  surgeon  compared  two  periods,  2007—2008  without  TA  and  2008—2009  with
TA. The  451  included  patients  underwent  primary  unilateral  hip  (n  =  261)  or  knee  (n  =  190)
replacement  for  osteoarthritis.  Standardised  protocols  were  used  for  surgery  and  anaesthe-
sia. TA  was  given  intravenously  in  a  dose  of  1  g  (i.e.,  15  mg/kg)  at  incision  and  wound  closure
then at  6-hour  intervals  for  24  hours.  Blood  losses  were  estimated  using  the  Mercuriali  formula.
Haemoglobin  on  D  —1  and  D  8  and  the  number  and  volume  of  autologous  (from  intra-operative
blood salvage)  and  homologous  blood  transfusions  were  collected.  The  costs  of  TA,  blood  sal-
us  blood  units  were  recorded.  The  two  groups  were  compared  usingvage systems,  and  homologo
Student’s  test,  Wilcoxon’s  test,  and  the  Khi2 test,  and  multivariate  analyses  were  performed.
Values of  p  less  than  0.05  were  considered  signiﬁcant.
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Results:  TA  use  was  associated  with  a  signiﬁcant  decrease  in  the  homologous  blood  transfusion
rate (from  4%  to  0%)  and  with  38%  and  68%  reductions  in  the  rate  and  volume  of  autologous  blood
transfusions,  respectively,  due  to  a  34%  decrease  in  blood  losses.  After  taking  into  account  the
additional  cost  of  TA  therapy,  there  was  a  25%  reduction  in  the  cost  of  the  blood  conservation
strategy.
Conclusion:  TA  therapy  abolished  the  need  for  homologous  blood  transfusion  and  induced  no
notable side  effects.  TA  therapy  decreased  the  amount  of  blood  salvaged  intra-operatively,
allowing  a  more  rational  use  of  the  blood  salvage  system  and  decreasing  the  cost  of  anaesthesia.
Level of  evidence:  IV.  Retrospective  case-control.
© 2012  Published  by  Elsevier  Masson  SAS.
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tourniquet  was  used.  Pulsed  lavage  was  performed  to
optimise  recipient  bone  preparation.  An  intraarticular
drain  was  inserted  then  removed  routinely  36  hours  after
surgery.ntroduction
steoarthritis  causes  functional  and  quality-of-life  impair-
ents  and  is  the  main  cause  of  morbidity  in  industrialised
ountries  [1].  Surgery  is  reserved  for  patients  with  primary
r  secondary  failure  of  conservative  management.  Total  hip
rthroplasty  (THA)  and  total  knee  arthroplasty  (TKA)  carry
 risk  of  bleeding.  The  incidence  of  major  bleeding  events
requiring  more  than  two  red-blood-cell  [RBC]  packs  or  reop-
ration  or  causing  death)  is  1.4%  [2].  Overall,  the  mean
ortality  rate  in  orthopaedic  surgery  is  less  than  1%  [3].
mportantly,  mortality  is  increased  5-fold  in  patients  with
naemia  [4].  Half  the  deaths  ascribable  entirely  or  in  part  to
nadequate  blood  management  during  anaesthesia  occur  in
rthopaedic  surgery  [5].  RBC  transfusion  is  the  only  currently
vailable  treatment  for  poorly  tolerated  acute  anaemia.
owever,  blood  transfusion  is  an  independent  risk  factor  for
eath  [4].  The  risks  and  costs  associated  with  blood  transfu-
ion,  together  with  challenges  in  obtaining  sufﬁcient  labile
lood  products,  have  generated  interest  in  blood-sparing
trategies.
Tranexamic  acid  (TA)  is  an  inexpensive  synthetic  antiﬁb-
inolytic  agent.  TA  prevents  the  degradation  of  ﬁbrin  and
elays  the  breakdown  of  haemostasis  clots.  A  30%  reduc-
ion  in  blood  transfusion  requirements  due  to  a  decrease
y  one-third  in  blood  losses  has  been  demonstrated  with
A  in  orthopaedic  surgery  [6].  However,  TA  is  used  in  only
7%  of  patients  meeting  theoretical  criteria  for  this  treat-
ent,  due  to  the  wide  variability  in  administration  regimens
dose,  duration,  and  route)  [7,8]. Furthermore,  the  poten-
ial  prothrombotic  effect  of  TA  is  a  source  of  concern
mong  orthopaedic  surgeons  and  has  not  been  investigated
n  speciﬁcally  designed  studies  providing  a  high-level  of
vidence.  In  our  centre,  intravenous  TA  is  given  intra-
peratively  and  postoperatively  according  to  a  protocol
ased  on  TA  pharmacokinetics  and  knowledge  of  postopera-
ive  ﬁbrinolysis.
The  primary  objective  of  this  study  was  to  conﬁrm  that
ur  TA  therapy  protocol  diminished  the  need  for  homolo-
ous  blood  transfusions  and  for  autologous  transfusion  of
lood  salvaged  intra-operatively  in  a  large  cohort  of  patients
ndergoing  scheduled  primary  lower-limb  joint  replacement
urgery  by  a  single  surgeon.  The  secondary  objective  was  to
etermine  whether  our  blood-sparing  strategy  was  associ-
ted  with  a  reduction  in  the  ﬁnancial  cost  of  surgery.aterial and methods
nclusion  and  exclusion  criteria
e  conducted  a  single-centre  retrospective  study  to  com-
are  two  groups  of  consecutive  patients  with  osteoarthritis
ho  underwent  scheduled  primary  unilateral  THA  or  TKA  by
 single  surgeon.  The  ﬁrst  group  consisted  of  the  patients
hose  joint  replacement  procedure  was  done  between  Jan-
ary  2007  and  October  2008,  none  of  whom  received  TA  (TA—
roup).  In  the  second  group,  surgery  was  performed  between
ovember  2008  and  December  2009  and  TA  was  administered
erioperatively  (TA+  group).  Exclusion  criteria  in  both  groups
ere  as  follows:
 medical  contraindication  to  TA,  i.e.,  history  of  seizures,
severe  renal  failure  (creatinine  clearance  <  30  mL/min),
bleeding  disorders,  history  of  venous  thromboembolism
(deep  vein  thrombosis  and/or  pulmonary  embolism)
and/or  of  arterial  thromboembolism  (angina,  myocardial
infarction,  stroke,  acute  lower-limb  ischaemia);
perioperative  anaemia  deﬁned  as  a  haemoglobin  (Hb)
level  lower  than  13  g/dL  in  males  and  12  g/dL  in  females.
Of  the  800  eligible  patients  over  the  two  periods,  203
id  not  have  all  the  inclusion  criteria  and  146  had  one
r  more  exclusion  criteria,  leaving  451  patients  for  the
tudy.
urgical  technique
he  surgical  technique  was  standardised  and  all  proce-
ures  were  done  by  the  same  surgeon  (JNA).  For  THA,
he  Watson-Jones  anterolateral  approach  was  used  and
 cementless  anatomic  prosthesis  was  implanted.  TKA
as  performed  via  the  minimally  invasive  peripatellar
pproach  without  patellar  eversion,  using  modern  instru-
entation  to  allow  bone  preparation  in  the  coronal  plane
9].  A  three-compartment  cemented  posterior-stabilised
rosthesis  with  a  mobile  plateau  was  implanted.  No
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Anaesthetic  technique
All  patients  were  evaluated  by  an  anaesthesiologist  one
month  before  surgery.  Antiplatelet  agents  were  interrupted
ﬁve  days  before  surgery,  after  discussion  with  the  patient’s
usual  cardiologist.  In  the  absence  of  medical  contraindi-
cations,  either  general  anaesthesia  or  spinal  anaesthesia
with  or  without  sedation  was  used.  The  patient  was  in  the
supine  position.  A  standardised  intravenous  ﬂuid  regimen
was  used:  500  mL  of  6%  hydroxyethyl  starch  colloid  (HES
[130  kDa])  at  anaesthesia  induction  followed  by  1000  mL  of
Ringer  Lactate® until  the  patient  was  returned  to  the  surgi-
cal  ward.
In  the  TA+  treated  group,  TA  was  given  as  a  30-minute
intravenous  infusion.  The  total  TA  dose  was  6  g:  1  g  (i.e.,
15  mg/kg)  before  the  incision,  at  wound  closure,  and  every
6  hours  for  24  hours  thereafter.  In  both  groups,  a  multi-
modal  regimen  was  used  for  postoperative  analgesia,  ﬁrst
intravenously  then  orally  starting  on  the  ﬁrst  postoperative
day:  paracetamol  combined  with  tramadol  or  nefopam,  plus
ketoprofen  (50  mg  every  6  hours)  for  three  to  ﬁve  days  in  the
absence  of  contraindications.  An  analgesic  nerve  block  was
performed  routinely  in  the  recovery  room,  either  a  fascia
iliaca  compartment  block  in  THA  patients  or  a  continuous
sciatic  nerve  block  with  a  femoral  catheter  for  72  hours
in  TKA  patients.  A  patient-controlled  morphine  pump  was
used  for  rescue  analgesia  if  needed.  The  prevention  of
venous  thromboembolism  relied  on  enoxaparin  40  mg  or  fon-
daparinux  sodium  2.5  mg  subcutaneously  starting  on  D1,
in  the  absence  of  contraindications  (creatinine  clearance
<  30  mL/min  and  active  bleeding).
Blood  transfusion  protocol
An  intra-operative  blood  salvage  device  was  used  routinely.
The  blood  was  processed  prior  to  infusion  by  automatic
sequential  washing  using  a  Cell  Saver  5+TM (Haemonetics,
Plaisir,  France)  when  the  volume  recovered  by  aspiration
(blood  and  rinsing  solution)  exceeded  1000  mL.  The  recir-
culated  autologous  blood  was  routinely  transfused  to  the
patient  in  the  recovery  room.  The  cut-offs  used  to  perform
homologous  blood  transfusion  were  those  recommended
by  the  French  Healthcare  Product  Safety  Agency  (Agence
franc¸aise  de  sécurité  sanitaire  des  produits  de  santé)  in  2002
[10]:
•  7  g/dL  of  Hb  in  patients  free  of  cardiovascular  disease;
•  8  to  9  g/dL  of  Hb  in  patients  with  established  cardiovas-
cular  disease  (coronary  artery  disease,  cerebrovascular
events,  peripheral  vascular  disease,  or  heart  failure)  or
multiple  cardiovascular  risk  factors  (age  >  45  years  in
males  and  >  55  years  in  females,  family  history  of  pre-
mature  cardiovascular  disease  [<  55  years  in  males  and
<  65  years  in  females],  hypertension,  diabetes,  smoking,
dyslipidaemia,  obesity);
•  10  g/dL  of  Hb  in  patients  with  poor  clinical  tolerance  of
lower  values.Intravenous  iron  supplementation  was  given  postoper-
atively  (200  mg  on  D  —1  and  D3)  if  the  preoperatively
predicted  blood  transfusion  risk  was  high  in  the  TA—  group
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nd  routinely  in  the  TA+  group  except  when  the  blood  trans-
usion  risk  was  low.
ata  collection
he  study  data  were  obtained  from  a  computerised  database
n  which  data  were  entered  prospectively  at  the  end  of
ach  arthroplasty  procedure.  For  all  patients,  we  collected
he  physical,  medical,  anaesthesiological,  and  surgical  char-
cteristics.  Total  blood  volume  (TBV)  was  estimated  using
ilcher’s  formula  [11]. To  estimate  the  blood  transfusion
isk,  we  computed  the  difference  between  estimated  blood
osses  (evaluated  at  10%  of  the  TBV  at  our  centre)  and  the
lood  loss  needed  to  reach  the  blood  transfusion  cut-off
TBV·[Haematocrit  (Ht)  D1—Ht  cut-off])  [12,13].  We  anal-
sed  the  following  variables:  blood  loss  estimated  using
ercuriali’s  formula  (TBV·[Ht  D-1—Ht  D8]  +  autologous  and
omologous  RBCs  transfused),  the  Hb  levels  on  D  —1  and
8,  the  homologous  transfusion  rate,  and  the  autologous
ransfusion  rate  and  volume  [14]. Patients  were  evaluated
linically  for  side  effects  of  TA  therapy  (thromboembolic
vents,  coronary  artery  events,  seizures,  vascular  events),
hich  were  recorded  in  each  group.
Simultaneously,  a  pharmaco-economic  study  was  con-
ucted.  We  took  into  account  the  cost  of  blood  transfusions
ased  on  the  cost  of  one  RBC  pack  (190  D),  of  cell  salvage
onsumables  (50  D),  and  of  the  salvaged  blood  processing
ystem  (100  D).  Each  TA  treatment  (6  g/patient)  cost  12  D.
he  overall  cost  was  then  converted  to  the  costs  per  patient
nd  per  group.
tatistical  analysis
he  two  groups  were  compared  using  the  Student  and
ilcoxon  tests  for  quantitative  variables  and  the  Khi2 test
or  qualitative  variables.  Values  of  p  less  than  0.05  were
onsidered  signiﬁcant.  Two  multivariate  analyses  were  con-
ucted  to  simultaneously  assess  the  inﬂuence  on  the  blood
ransfusion  rate  of  TA,  non-steroidal  anti-inﬂammatory
rugs  (NSAIDs),  and  intravenous  iron  given  postoperatively
logistic  regression  analysis)  and  of  estimated  blood  losses
ANOVA).
esults
f  the  451  study  patients,  241  did  not  receive  TA  and  210
eceived  TA  (Table  1).  All  demographic  characteristics  were
imilar  in  the  two  groups  (P,  NS).  Mean  patient  age  was
0  years  (39—89  years)  in  the  TA— group  and  69  years
33—90  years)  in  the  TA+  group.  The  male-to-female  ratio
as  1.  The  two  types  of  surgical  procedures  were  evenly
istributed  between  the  two  groups:  in  the  TA— group,
40  (58%)  patients  underwent  THA  and  101  (42%)  TKA,  and
he  corresponding  values  in  the  TA+  group  were  121  (58%)
nd  89  (42%),  respectively.  Mean  operative  time  was  75  min
40—145  min)  in  the  AT—  group  and  78  min  (45—160  min)  in
he  AT+  group.  General  anaesthesia  was  used  in  187  (78%)
f  the  241  TA—  patients  and  161  (77%)  of  the  210  AT+
atients  and  spinal  anaesthesia  in  54  (22%)  TA—  patients  and
9  (23%)  TA+  patients.  For  thromboembolism  prevention,
480  E.  Irisson  et  al.
Table  1  Demographic  and  medical  characteristics  of  the  study  patients.  The  data  are  mean  ±  SD  or  numbers.
THA  (n  =  261)  TKA  (n  =  190)
TA— (n  =  140)  TA+  (n  =  121)  TA—  (n  =  101)  TA+  (n  =  89)
Age  (years)  66  ±  10  66  ±  10  72  ±  7  72  ±  8
Body weight  (kg)  75  ±  16  78  ±  15  79  ±  14  81  ±  16
Height (cm) 169  ±  9  169  ±  9  166  ±  9  166  ±  9
Males/females,  n 75/65 66/55 38/63 40/49
TBV  (mL) 5300  ±  1220 5440  ±  1080 5375  ±  930 5570  ±  1050
Creatinine clearance  (mL/min) 86  ±  28 87  ±  27 79  ±  25 83  ±  28
Blood transfusion  cut-off7/8—9/10  g/dL,  n  8/131/1  6/112/3  0/101/0  0/89/0
Operative time  (min)  74  ±  22  75  ±  21  86  ±  19  88  ±  17
Spinal anaesthesia/GA,  n  22/118  24/97  32/69  25/64
Fondaparinux/enoxaparin,  n  40/100  37/84  18/83  20/69
Postoperative  NSAIDs,  n  129  97*  97  67*
Postoperative  IV  iron,  n  35  110*  37  80*
THA: total hip arthroplasty; TKA: total knee arthroplasty; TA—: group managed without tranexamic acid; TA+: group managed with
ia; NS
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*P < 0.05 versus the group managed without tranexamic acid.
ondaparinux  was  used  in  58  (24%)  TA—  patients  and  57  (27%)
A+  patients  and  enoxaparin  in  183  (76%)  TA—  patients  and
53  (73%)  TA+  patients.  NSAID  therapy  was  prescribed  in
 signiﬁcantly  larger  proportion  of  TA—  than  TA+  patients
226/241,  94%  versus  164/210,  78%,  respectively;  P  <  0.001)
nd  intravenous  iron  in  a  signiﬁcantly  smaller  proportion
f  TA—  than  TA+  patients  (73/241,  30%  and  190/210,  90%,
espectively;  P  <  0.001).
Blood  losses  estimated  using  Mercuriali’s  formula  were
ower  by  34%  in  the  TA+  group  compared  to  the  TA—
roup  (1260  ±  620  mL  versus  1900  ±  690  mL,  P <  0.001).  The
b  level  on  D-1  was  14  ±  1  g/dL  in  the  TA— group  and
4.2  ±  1  g/dL  in  the  TA+  group  (P  =  0.21).  On  D8,  the  Hb
evel  was  signiﬁcantly  higher  in  the  TA+  group  than  in  the
A— group  (11.8  ±  1.2  g/dL  versus  10.7  ±  1.2  g/dL,  P  <  0.001)
Fig.  1).  The  difference  between  the  initial  and  ﬁnal  Hb  lev-
ls  was  -3.3  ±  1.2  g/dL  in  the  TA—  group  and  -2.4  ±  1.1  g/dL
n  the  TA+  group  (p  <  0.001).  In  keeping  with  the  reduction
n  blood  losses,  the  TA+  group  required  signiﬁcantly  fewer
omologous  blood  transfusions  compared  to  the  TA—  group
igure  1  Changes  in  mean  haemoglobin  level  (mean  ±  SD).
p <  0.05  versus  the  group  without  tranexamic  acid.  TA—:  group
anaged  without  tranexamic  acid;  TA+:  group  managed  with
ranexamic  acid.
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dAIDs: non-steroidal anti-inﬂammatory drugs; IV: intravenous.
0/210  versus  10/241,  4%,  P  =  0.003)  (Table  2).  Most  of  the
eduction  in  homologous  blood  transfusions  was  ascribable
o  the  TKA  group  (0  versus  7%,  P  =  0.03).  The  number  of
utologous  blood  transfusions  of  recirculated  blood  was  38%
ower  in  the  TA+  group  (123/210,  59%  versus  234/241,  97%
n  the  TA—  group,  P  <  0.001).  Again,  the  reduction  in  homol-
gous  blood  transfusions  was  greater  in  the  TKA  patients
18%  with  TA  versus  96%  without  TA,  P  <  0.001).  The  vol-
me  of  autologous  blood  transfusions  was  68%  lower  in  the
A+  group  compared  to  the  TA— group  (110  ±  125  mL  ver-
us  350  ±  190  mL,  P  <  0.001).  After  adjustment  for  the  use
f  intravenous  iron  and  NSAIDs,  TA  therapy  remained  sig-
iﬁcantly  associated  with  reductions  in  the  overall  blood
ransfusion  rate  (z  =  —6.6;  P  <  0.001)  and  estimated  blood
osses  (F  =  35.3;  P  <  0.001).
During  the  postoperative  period,  one  patient  in  the  TA—
roup  experienced  pulmonary  embolism  and  1  patient  in  the
A+  group  had  an  episode  of  angina  pectoris.  No  seizures
ere  recorded  during  the  hospital  stay.
The  total  cost  of  blood  transfusions  was  38,870  D  in
he  TA—  group  and  22,800  D  in  the  TA+  group.  When  tak-
ng  the  cost  of  TA  treatment  into  account  (2520  D  for  the
ntire  group),  the  overall  cost  savings  in  the  TA+  group  were
3,350  D.  Mean  cost  of  blood  transfusions  and  TA  therapy  per
atient  was  estimated  at  162  D  in  the  TA—  group  and  121  D
n  the  TA+  group,  indicating  a 25%  reduction  in  the  cost  of
naesthesiological  management.
iscussion
n  our  clinical  study,  perioperative  treatment  with  TA  signi-
cantly  decreased  the  blood  transfusion  rates  and  the  cost
f  anaesthesiological  management.  For  surgical  procedures
arrying  a  high  risk  of  bleeding,  the  morbidity  and  mortality
ssociated  with  anaemia  must  be  weighed  against  the  risks
ssociated  with  blood  transfusions  [4].  On  the  one  hand,
ostoperative  anaemia  —– found  in  90%  of  patients  after
rthroplasty  —– increases  the  risk  of  myocardial  infarction
ue  to  a  mismatch  between  oxygen  supply  and  requirements
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Table  2  Effect  of  tranexamic  acid  therapy  in  decreasing  blood  losses  and  blood  transfusion  requirements.  The  data  are
mean ±  SD,  number,  or  percentage.
TA—  (n  =  241)  TA+  (n  =  210)
Hb  D1  (g/dL)  14.0  ±  1  14.2  ±  1
Hb D8  (g/dL)  10.7  ±  1.2  11.8  ±  1.2*
Total blood  losses  (mL)  1900  ±  690  1260  ±  620*
Homologous blood  transfusions,  n  of  patients  10  0*
N (1,  2,  or  3)  of  RBC  packs  in  homologous  blood  transfusions,  n  of  patients  3/6/1  0
Autologous blood  transfusion  rate  (%) 97  59*
Volume of  autologous  blood  transfusions  (mL) 350  ±  190 110  ±  125*
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ConclusionTA—: group managed without tranexamic acid; TA+: group manage
*P < 0.001 versus the group managed without tranexamic acid.
during  the  perioperative  period,  and  myocardial  infarc-
tion  is  the  leading  cause  of  death  after  major  orthopaedic
procedures  [15,16].  However,  the  use  of  restrictive  blood
transfusion  strategies  does  not  increase  mortality  [17]. On
the  other  hand,  transfusion  of  labile  blood  products  carries
potentially  life-threatening  risks  (e.g.,  incompatibility  and
pulmonary  oedema)  [18]. TA  therapy  is  among  the  available
blood-sparing  strategies.  Studies  have  provided  high-level
evidence  that  TA  therapy  is  effective.  In  addition,  no  side
effects  have  been  reported,  and  the  cost  of  TA  is  low.  Never-
theless,  TA  is  rarely  used  in  everyday  practice  [6—8], in  large
part  because  no  consensus  exists  about  the  best  administra-
tion  regimen.
Our  clinical  study  designed  to  conﬁrm  the  beneﬁcial
effects  of  TA  given  during  and  after  joint  replacement
surgery  compared  two  populations  of  patients  who  under-
went  scheduled  unilateral  THA  or  TKA.  The  retrospective
design  is  an  inherent  limitation.  However,  our  cohort  is
large,  whereas  most  of  the  meTA—analyses  on  TA  ther-
apy  in  orthopaedic  surgery  rest  on  studies  of  fewer  than
150  patients  [19,20].  Importantly,  all  procedures  were  per-
formed  by  the  same  surgeon  and  the  TA  treatment  protocol
was  standardised.  Patients  with  contraindications  to  TA  ther-
apy  were  excluded  from  both  groups.  Confounding  may
have  occurred,  due  to  the  differences  in  the  proportions
of  patients  given  NSAIDs  and  intravenous  iron  between  the
two  groups.  NSAIDs  are  used  to  minimise  the  risk  of  peripros-
thetic  ossiﬁcation,  but  they  inhibit  platelet  activation  and
cause  a  slight  increase  in  the  incidence  of  abnormal  oper-
ative  site  bleeding  (of  about  1%)  [21,22].  Intravenous  iron
supplementation  accelerates  recovery  from  postoperative
anaemia.  However,  the  effect  of  iron  supplementation  on
the  Hb  level  takes  more  than  1  week  to  develop,  as  the
inﬂammatory  state  seen  during  the  ﬁrst  15  postoperative
days  is  associated  with  relative  deﬁciency  and  inefﬁciency
of  the  endogenous  erythropoietin  needed  for  erythropoiesis
to  occur  [23,24].
We computed  blood  losses  in  our  patients,  because  mea-
suring  blood  losses  during  surgery  underestimates  actual
blood  losses  by  about  50%  [25]. Preoperative  anaemia  was
an  exclusion  criterion,  as  erythropoietin  therapy  is  required
in  this  situation  [26]  and  may  bias  the  Hb  level  evaluation  on
D8,  resulting  in  underestimation  of  blood  losses  computed
based  on  this  parameter.  The  TA  treatment  protocol  used
at  our  centre  is  based  on  knowledge  of  TA  pharmacokinet-
ics  and  of  postarthroplasty  ﬁbrinolysis.  Peak  serum  TA  levels
M
sh tranexamic acid; Hb: haemoglobin; D: day; RBC: red blood cell.
re  reached  immediately  upon  intravenous  administration.
he  elimination  half-life  is  3  hours.  The  effect  of  TA  seems
o  be  dose-dependent  (>  30  mg/kg  in  all)  [6].  No  additional
eneﬁts  are  obtained  by  increasing  the  bolus  dose  above  10
o  15  mg/kg  [27]. The  cumulative  dose  used  at  our  centre
s  higher  than  in  most  of  the  reported  TA  treatment  regi-
ens  [28]. However,  ﬁbrinolysis  activation  persists  for  12  to
4  hours  after  surgery,  supporting  the  prolonged  use  of  TA
uring  the  postoperative  period,  which  has  been  reported
o  increase  efﬁcacy  [29].
Blood  losses  were  diminished  by  34%  in  our  TA+  group
8,30].  The  result  was  a  smaller  overall  Hb  decrease  with  a
igher  ﬁnal  Hb  level  [31]. Our  results  also  conﬁrm  the  efﬁ-
acy  of  TA  therapy  in  diminishing  homologous  and  autologous
lood  transfusion  requirements  in  patients  undergoing  major
rthopaedic  surgery  [6,19,32].  The  decreased  rate  and  vol-
me  of  autologous  blood  transfusions  directly  reﬂected  the
bility  of  TA  therapy  to  diminish  bleeding  and  showed  that
he  yield  of  intra-operative  blood  salvage  in  terms  of  blood
ransfusions  was  poor.  Earlier  studies  showed  that  intra-
perative  blood  salvage  systems  were  used  on  average  in
6%  of  THAs  and  40%  of  TKAs  [6].  Intra-operative  blood  sal-
age  adds  to  the  cost  of  surgery  and  carries  speciﬁc  risks
uch  as  bacterial  contamination,  gas  embolism,  and  acute
aemolysis  [33]. The  present  study  served  as  an  evaluation
f  professional  practices  study  at  our  centre  and,  based  on
ts  results,  intra-operative  blood  salvage  is  no  longer  used
outinely.  The  effect  of  TA  therapy  was  larger  in  the  TKA
roup,  in  keeping  with  earlier  data,  as  ﬁbrinolysis  activa-
ion  in  the  postoperative  period  is  more  marked  than  after
HA,  particularly  when  a  tourniquet  is  used  [6,34].
The  cost  of  blood  salvage  was  decreased  by  25%  when
A  was  used.  The  simple  cost  evaluation  performed  for  our
tudy  underestimated  total  costs,  as  we  did  not  consider
he  cost  of  purchasing  and  maintaining  the  Cell  SaverTM
achine  or  the  costs  related  to  the  personnel  in  charge  of
etting  up  this  technique.  The  cost  savings  associated  with
A  treatment  are  further  increased  by  the  savings  related  to
ecreased  use  of  the  intra-operative  blood  salvage  system.
n  earlier  study  suggested  a  cost-saving  effect  of  TA  therapy
elated  to  a  decrease  in  hospital  stay  length  [35].inimising  blood  transfusion  requirements  in  orthopaedic
urgery  rests  on  the  development  of  protocols  that  are
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peciﬁc  of  each  department  and  can  be  adjusted  to  each
ndividual  patient.  These  protocols  should  rely  on  multi-
le  blood-sparing  techniques.  The  present  study  in  a  large
atient  cohort  conﬁrms  that  TA  therapy  decreases  homol-
gous  and  autologous  blood  transfusion  requirements  and
iminishes  blood  losses.  TA  therapy  decreases  the  risk  of
lood  transfusion  without  increasing  the  risk  of  postop-
rative  anaemia.  A  rational  regimen  of  TA  therapy  given
ntra-operatively  and  postoperatively  seems  effective  and
evoid  of  notable  side  effects.  TA  therapy  was  directly  asso-
iated  with  a  reduction  in  the  costs  of  treatment  in  our
tudy.  In  addition,  this  study  served  as  an  evaluation  of
rofessional  practices,  and  its  results  led  to  intra-operative
lood  salvage  no  longer  being  routinely  used  at  our  centre,
iven  its  limited  impact  in  patients  treated  with  TA.
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